Blog article

Say hello to our new CEO

Andrew joined Immunocore as Chief Commercial Officer in October 2017 and stepped up into the role of CEO in February 2018. He received his degree in Biochemistry from Cardiff University and now has more than 30 years of experience in the pharmaceutical sector. Andrew joined Immunocore from Eli Lilly & Co, where he served in a number of global leadership positions across multiple therapeutic areas and geographies.

Want to know more? Here are 8 Facts about our new CEO:

  1. Grew up in Doncaster.
  2. Went to University in Cardiff, where he studied Biochemistry. Whilst here he captained Welsh Universities Rugby.
  3. He’s been married to his wife for 30 years and has three children; 2 girls (25 & 23) and a son (20)
  4. He has two dogs – Cavalier King Charles Spaniels.
  5. In his spare time he likes watching sport (in particular Rugby), keeping fit, mini triathlons, sea fishing and scuba diving.
  6. He speaks business fluent Italian.
  7. When he was younger he wanted to have a job that combined his two loves; science and sport.
  8. And what gets him out of bed every morning is that he enjoys working in an environment with a strong sense of purpose, working with talented people, having fun and continuing to learn.

Speaking to Business and Innovation magazine, in May 2018, Andrew said: “I joined Immunocore because of the exciting science that underpins the technology. I believe that our platform and portfolio of product has the potential to significantly help patients.­”

These are indeed exciting times, as our first lead product, IMCgp100, is currently undergoing clinical trials for the treatment of metastatic uveal melanoma (a cancer of the eye that has an exceptionally high unmet medical need).

“We believe this therapy has the potential to be a game-changer for medical practice in this devastating condition," explains Andrew. We’re optimistic that the encouraging data we have seen has the potential to read across to other ImmTAC programmes, especially when addressing difficult to treat tumours which have proven challenging for other therapies. We are excited by the possibilities of tl1e ImmTAC platform in cancer and beyond."